Other Information.
−Removed: On May 10, 2023, a Rule 10b5-1 trading arrangement adopted on May 10, 2022 by Stephen Pakola , M.D., our EVP, Chief Medical Officer , which was intended to satisfy the affirmative defense of Rule 10b5-1(c) (the " Rule 10b5-1 Plan "), expired pursuant to its terms.
−Removed: In the aggregate 3,138 shares of our common stock were sold under the Rule 10b5-1 Plan prior to its expiration.
−Removed: Other than as described above, during the three months ended June 30, 2023, none of our directors or Section 16 reporting officers adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of the SEC's Regulation S-K).
+Added: Rule 10b5-1 Trading Plans
+Added: The adoption or termination of contracts, instructions or written plans for the purchase or sale of our securities by our Section 16 officers and directors for the three months ended September 30, 2023, each of which is intended to satisfy the affirmative defense of Rule 10b5-1(c) ("Rule 10b5-1 Plan"), were as follows:
+Added: Aggregate # of
+Added: Securities to be
+Added: Expiration Date
+Added: Purchased/Sold
+Added: Stephen Pakola, M.D.
+Added: Executive Vice President, Chief Medical Officer
+Added: President and Chief Executive Officer
+Added: Other than as described above, during the three months ended September 30, 2023, none of our directors or Section 16 reporting officers adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of the SEC's Regulation S-K).
Incorporated by Reference
1 unchanged sentence
Amended and Restated Bylaws
+Added: ATM Equity Offering SM Sales Agreement, dated as of September 1, 2023, between BofA Securities, Inc.
+Added: and REGENXBIO Inc.
Certification of the Chief Executive Officer, as required by Section 302 of the Sarbanes-Oxley Act of 2002
1 unchanged sentence
Certifications of the Chief Executive Officer and Chief Financial Officer as required by 18 U.S.C.
−Removed: The following materials from the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2023 formatted in Inline XBRL (eXtensible Business Reporting Language):
+Added: The following materials from the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2023 formatted in Inline XBRL (eXtensible Business Reporting Language):
(i) Consolidated Balance Sheets
3 unchanged sentences
(v) Notes to Consolidated Financial Statements
−Removed: The cover page from the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2023 formatted in Inline XBRL (included in Exhibit 101)
+Added: The cover page from the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2023 formatted in Inline XBRL (included in Exhibit 101)
The certification attached as Exhibit 32.1 that accompanies this Quarterly Report on Form 10-Q is not deemed filed with the SEC and is not to be incorporated by reference into any filing of REGENXBIO Inc.
2 unchanged sentences
REGENXBIO Inc.
−Removed: August 2, 2023
+Added: November 8, 2023
/s/ Kenneth T.
1 unchanged sentence
(Principal Executive Officer)
−Removed: August 2, 2023
+Added: November 8, 2023
/s/ Vittal Vasista
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.